Cargando…

Dual effect of DLBCL-derived EXOs in lymphoma to improve DC vaccine efficacy in vitro while favor tumorgenesis in vivo

BACKGROUND: Exosomes derived from tumor cells (TEXs) are involved in both immune suppression, angiogenesis, metastasis and anticancer stimulatory, but the biological characteristics and role of diffuse large B cell lymphoma (DLBCL)-derived exosomes have been less investigated. METHODS: Exosomes (EXO...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Zhenzhen, You, Liangshun, Wang, Lei, Huang, Xianbo, Liu, Hui, Wei, Ju ying, Zhu, Li, Qian, Wenbin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6090784/
https://www.ncbi.nlm.nih.gov/pubmed/30103789
http://dx.doi.org/10.1186/s13046-018-0863-7
_version_ 1783347258692993024
author Chen, Zhenzhen
You, Liangshun
Wang, Lei
Huang, Xianbo
Liu, Hui
Wei, Ju ying
Zhu, Li
Qian, Wenbin
author_facet Chen, Zhenzhen
You, Liangshun
Wang, Lei
Huang, Xianbo
Liu, Hui
Wei, Ju ying
Zhu, Li
Qian, Wenbin
author_sort Chen, Zhenzhen
collection PubMed
description BACKGROUND: Exosomes derived from tumor cells (TEXs) are involved in both immune suppression, angiogenesis, metastasis and anticancer stimulatory, but the biological characteristics and role of diffuse large B cell lymphoma (DLBCL)-derived exosomes have been less investigated. METHODS: Exosomes (EXOs) were isolated from OCI-LY3, SU-DHL-16, and Raji cells and biological characteristics of EXOs were investigated using electron microscopy, flow cytometry analysis, and Western blot analysis. The protein expression of EXOs was determined by an antibody array. Next, the communication between EXOs and lymphoma cell, stromal cell, dendritic cells (DCs), and T cells was evaluated. Finally, effect of DLBCL TEXs on tumor growth in vivo was investigated. RESULTS: We demonstrated that EXOs derived from DLBCL cell lines displayed malignancy molecules such as c-Myc, Bcl-2, Mcl-1, CD19, and CD20. There was a different protein expression pattern between DLBCL TEXs and Burkitt lymphoma TEXs. DLBCL TEXs were easily captured by DCs and lymphoma cells, and mainly acted as an immunosuppressive mediator, evidenced by induction of apoptosis and upregulation of PD-1 in T cells. Furthermore, the TEXs stimulated not only cell proliferation, migration of stromal cells but also angiogenesis. As a result, the TEXs promoted tumor growth in vivo. On other hand, DLBCL TEXs did not induce apoptosis of DCs. After pulsed with the TEXs, DCs could stimulate clonal expansion of T cells, increase the secretion of IL-6 and TNFα, and decrease the production of immunosuppressive cytokine IL-4 and IL-10. The T cells from tumor bearing mice immunized by TEX were shown to possess superior antilymphoma potency relative to immunization of tumor lysates. CONCLUSIONS: This study provides the framework for novel immunotherapies targeting TEXs in DLBCL. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13046-018-0863-7) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6090784
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-60907842018-08-17 Dual effect of DLBCL-derived EXOs in lymphoma to improve DC vaccine efficacy in vitro while favor tumorgenesis in vivo Chen, Zhenzhen You, Liangshun Wang, Lei Huang, Xianbo Liu, Hui Wei, Ju ying Zhu, Li Qian, Wenbin J Exp Clin Cancer Res Research BACKGROUND: Exosomes derived from tumor cells (TEXs) are involved in both immune suppression, angiogenesis, metastasis and anticancer stimulatory, but the biological characteristics and role of diffuse large B cell lymphoma (DLBCL)-derived exosomes have been less investigated. METHODS: Exosomes (EXOs) were isolated from OCI-LY3, SU-DHL-16, and Raji cells and biological characteristics of EXOs were investigated using electron microscopy, flow cytometry analysis, and Western blot analysis. The protein expression of EXOs was determined by an antibody array. Next, the communication between EXOs and lymphoma cell, stromal cell, dendritic cells (DCs), and T cells was evaluated. Finally, effect of DLBCL TEXs on tumor growth in vivo was investigated. RESULTS: We demonstrated that EXOs derived from DLBCL cell lines displayed malignancy molecules such as c-Myc, Bcl-2, Mcl-1, CD19, and CD20. There was a different protein expression pattern between DLBCL TEXs and Burkitt lymphoma TEXs. DLBCL TEXs were easily captured by DCs and lymphoma cells, and mainly acted as an immunosuppressive mediator, evidenced by induction of apoptosis and upregulation of PD-1 in T cells. Furthermore, the TEXs stimulated not only cell proliferation, migration of stromal cells but also angiogenesis. As a result, the TEXs promoted tumor growth in vivo. On other hand, DLBCL TEXs did not induce apoptosis of DCs. After pulsed with the TEXs, DCs could stimulate clonal expansion of T cells, increase the secretion of IL-6 and TNFα, and decrease the production of immunosuppressive cytokine IL-4 and IL-10. The T cells from tumor bearing mice immunized by TEX were shown to possess superior antilymphoma potency relative to immunization of tumor lysates. CONCLUSIONS: This study provides the framework for novel immunotherapies targeting TEXs in DLBCL. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13046-018-0863-7) contains supplementary material, which is available to authorized users. BioMed Central 2018-08-13 /pmc/articles/PMC6090784/ /pubmed/30103789 http://dx.doi.org/10.1186/s13046-018-0863-7 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Chen, Zhenzhen
You, Liangshun
Wang, Lei
Huang, Xianbo
Liu, Hui
Wei, Ju ying
Zhu, Li
Qian, Wenbin
Dual effect of DLBCL-derived EXOs in lymphoma to improve DC vaccine efficacy in vitro while favor tumorgenesis in vivo
title Dual effect of DLBCL-derived EXOs in lymphoma to improve DC vaccine efficacy in vitro while favor tumorgenesis in vivo
title_full Dual effect of DLBCL-derived EXOs in lymphoma to improve DC vaccine efficacy in vitro while favor tumorgenesis in vivo
title_fullStr Dual effect of DLBCL-derived EXOs in lymphoma to improve DC vaccine efficacy in vitro while favor tumorgenesis in vivo
title_full_unstemmed Dual effect of DLBCL-derived EXOs in lymphoma to improve DC vaccine efficacy in vitro while favor tumorgenesis in vivo
title_short Dual effect of DLBCL-derived EXOs in lymphoma to improve DC vaccine efficacy in vitro while favor tumorgenesis in vivo
title_sort dual effect of dlbcl-derived exos in lymphoma to improve dc vaccine efficacy in vitro while favor tumorgenesis in vivo
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6090784/
https://www.ncbi.nlm.nih.gov/pubmed/30103789
http://dx.doi.org/10.1186/s13046-018-0863-7
work_keys_str_mv AT chenzhenzhen dualeffectofdlbclderivedexosinlymphomatoimprovedcvaccineefficacyinvitrowhilefavortumorgenesisinvivo
AT youliangshun dualeffectofdlbclderivedexosinlymphomatoimprovedcvaccineefficacyinvitrowhilefavortumorgenesisinvivo
AT wanglei dualeffectofdlbclderivedexosinlymphomatoimprovedcvaccineefficacyinvitrowhilefavortumorgenesisinvivo
AT huangxianbo dualeffectofdlbclderivedexosinlymphomatoimprovedcvaccineefficacyinvitrowhilefavortumorgenesisinvivo
AT liuhui dualeffectofdlbclderivedexosinlymphomatoimprovedcvaccineefficacyinvitrowhilefavortumorgenesisinvivo
AT weijuying dualeffectofdlbclderivedexosinlymphomatoimprovedcvaccineefficacyinvitrowhilefavortumorgenesisinvivo
AT zhuli dualeffectofdlbclderivedexosinlymphomatoimprovedcvaccineefficacyinvitrowhilefavortumorgenesisinvivo
AT qianwenbin dualeffectofdlbclderivedexosinlymphomatoimprovedcvaccineefficacyinvitrowhilefavortumorgenesisinvivo